Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphangioleiomyomatosis clinical trials
6 of 11 indexed Lymphangioleiomyomatosis trials are currently recruiting.
11 US clinical trials · 6 currently recruiting
Lymphangioleiomyomatosis is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 3 of these trials.
The research picture
Lymphangioleiomyomatosis has 11 registered US clinical trials, 6 of them open to new participants right now, about 55% of the total.
- 6
- recruiting participants now
- 55%
- of trials open to enrollment
- 1
- in Phase 3–4 (later-stage)
- 3
- top sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active & Recent Trials
11 total, page 1 of 1
TSC Biosample Repository and Natural History Database
National Tuberous Sclerosis Association
NCT05676099
Study of the Disease Process of Lymphangioleiomyomatosis
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001465
Safety and Durability of Sirolimus for Treatment of LAM
University of Cincinnati
NCT02432560
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
David M. Ritter
NCT06160310
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
National Heart, Lung, and Blood Institute (NHLBI)
NCT01799538
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
Columbia University
NCT06889168
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
NCT01552434
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
University of Cincinnati
NCT03150914
Feasibility of [11C]Acetate-PET in LAM and TSC
Brigham and Women's Hospital
NCT05467397
Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
National Heart, Lung, and Blood Institute (NHLBI)
NCT00552955
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Novartis Pharmaceuticals
NCT01059318
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Lymphangioleiomyomatosis Trial Landscape
11 indexed Lymphangioleiomyomatosis studies · 6 recruiting (55%).
Phase mix: 1 late (III/IV) vs 5 early (I/II).
Top sponsor: National Heart, Lung, and Blood Institute (NHLBI) (3 trials), 7 others listed. 11 shown below, recruiting first.
How to read this condition's trial landscape
That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Lymphangioleiomyomatosis?
PlainTrial tracks 11 US clinical trials for Lymphangioleiomyomatosis, of which 6 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Lymphangioleiomyomatosis?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.